Bevacizumab Alone Versus Dose-dense Temozolomide Followed by Bevacizumab for Recurrent Glioblastoma, Phase III
Status:
Recruiting
Trial end date:
2025-11-10
Target enrollment:
Participant gender:
Summary
The aim of this Phase III study is to evaluate the superiority of dose-dense temozolomide
(ddTMZ) followed by bevacizumab at ddTMZ failure for glioblastoma at first recurrence or
progression, comparing to bevacizumab alone.